48
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Automated Diagnosis of Plus Disease in Retinopathy of Prematurity Using Deep Convolutional Neural Networks

      1 , 2 , 1 , 1 , 2 , 3 , 4 , 4 , 4 , 1 , 5 , 2 , 6 , for the Imaging and Informatics in Retinopathy of Prematurity (i-ROP) Research Consortium
      JAMA Ophthalmology
      American Medical Association (AMA)

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <div class="section"> <a class="named-anchor" id="ab-eoi180038-1"> <!-- named anchor --> </a> <h5 class="section-title" id="d3627587e463">Question</h5> <p id="d3627587e465">Can an algorithm based on deep learning achieve expert-level performance at diagnosing plus disease in retinopathy of prematurity? </p> </div><div class="section"> <a class="named-anchor" id="ab-eoi180038-2"> <!-- named anchor --> </a> <h5 class="section-title" id="d3627587e468">Finding</h5> <p id="d3627587e470">In this technology evaluation study including 5511 retinal photographs, using 5-fold cross-validation, the algorithm achieved mean areas under the receiver operating characteristic curve of 0.94 and 0.99 for the diagnoses of normal and plus disease, respectively. On an independent test set of 100 images, the algorithm achieved 91% accuracy and a quadratic-weighted κ coefficient of 0.92, outperforming 6 of 8 retinopathy of prematurity experts. </p> </div><div class="section"> <a class="named-anchor" id="ab-eoi180038-3"> <!-- named anchor --> </a> <h5 class="section-title" id="d3627587e473">Meaning</h5> <p id="d3627587e475">These findings suggest the proposed algorithm can objectively diagnose plus disease with a proficiency comparable with human experts. </p> </div><p class="first" id="d3627587e478">This technology evaluation study examines the validity of an algorithm based on deep learning for automated diagnosis of plus disease in retinopathy of prematurity from retinal photographs. </p><div class="section"> <a class="named-anchor" id="ab-eoi180038-4"> <!-- named anchor --> </a> <h5 class="section-title" id="d3627587e482">Importance</h5> <p id="d3627587e484">Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide. The decision to treat is primarily based on the presence of plus disease, defined as dilation and tortuosity of retinal vessels. However, clinical diagnosis of plus disease is highly subjective and variable. </p> </div><div class="section"> <a class="named-anchor" id="ab-eoi180038-5"> <!-- named anchor --> </a> <h5 class="section-title" id="d3627587e487">Objective</h5> <p id="d3627587e489">To implement and validate an algorithm based on deep learning to automatically diagnose plus disease from retinal photographs. </p> </div><div class="section"> <a class="named-anchor" id="ab-eoi180038-6"> <!-- named anchor --> </a> <h5 class="section-title" id="d3627587e492">Design, Setting, and Participants</h5> <p id="d3627587e494">A deep convolutional neural network was trained using a data set of 5511 retinal photographs. Each image was previously assigned a reference standard diagnosis (RSD) based on consensus of image grading by 3 experts and clinical diagnosis by 1 expert (ie, normal, pre–plus disease, or plus disease). The algorithm was evaluated by 5-fold cross-validation and tested on an independent set of 100 images. Images were collected from 8 academic institutions participating in the Imaging and Informatics in ROP (i-ROP) cohort study. The deep learning algorithm was tested against 8 ROP experts, each of whom had more than 10 years of clinical experience and more than 5 peer-reviewed publications about ROP. Data were collected from July 2011 to December 2016. Data were analyzed from December 2016 to September 2017. </p> </div><div class="section"> <a class="named-anchor" id="ab-eoi180038-7"> <!-- named anchor --> </a> <h5 class="section-title" id="d3627587e497">Exposures</h5> <p id="d3627587e499">A deep learning algorithm trained on retinal photographs.</p> </div><div class="section"> <a class="named-anchor" id="ab-eoi180038-8"> <!-- named anchor --> </a> <h5 class="section-title" id="d3627587e502">Main Outcomes and Measures</h5> <p id="d3627587e504">Receiver operating characteristic analysis was performed to evaluate performance of the algorithm against the RSD. Quadratic-weighted κ coefficients were calculated for ternary classification (ie, normal, pre–plus disease, and plus disease) to measure agreement with the RSD and 8 independent experts. </p> </div><div class="section"> <a class="named-anchor" id="ab-eoi180038-9"> <!-- named anchor --> </a> <h5 class="section-title" id="d3627587e507">Results</h5> <p id="d3627587e509">Of the 5511 included retinal photographs, 4535 (82.3%) were graded as normal, 805 (14.6%) as pre–plus disease, and 172 (3.1%) as plus disease, based on the RSD. Mean (SD) area under the receiver operating characteristic curve statistics were 0.94 (0.01) for the diagnosis of normal (vs pre–plus disease or plus disease) and 0.98 (0.01) for the diagnosis of plus disease (vs normal or pre–plus disease). For diagnosis of plus disease in an independent test set of 100 retinal images, the algorithm achieved a sensitivity of 93% with 94% specificity. For detection of pre–plus disease or worse, the sensitivity and specificity were 100% and 94%, respectively. On the same test set, the algorithm achieved a quadratic-weighted κ coefficient of 0.92 compared with the RSD, outperforming 6 of 8 ROP experts. </p> </div><div class="section"> <a class="named-anchor" id="ab-eoi180038-10"> <!-- named anchor --> </a> <h5 class="section-title" id="d3627587e512">Conclusions and Relevance</h5> <p id="d3627587e514">This fully automated algorithm diagnosed plus disease in ROP with comparable or better accuracy than human experts. This has potential applications in disease detection, monitoring, and prognosis in infants at risk of ROP. </p> </div>

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

          To determine whether earlier treatment using ablation of the avascular retina in high-risk prethreshold retinopathy of prematurity (ROP) results in improved grating visual acuity and retinal structural outcomes compared with conventional treatment. Infants with bilateral high-risk prethreshold ROP (n = 317) had one eye randomized to early treatment with the fellow eye managed conventionally (control eye). In asymmetric cases (n = 84), the eye with high-risk prethreshold ROP was randomized to early treatment or conventional management. High risk was determined using a model based on the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity natural history cohort. At a corrected age of 9 months, visual acuity was assessed by masked testers using the Teller acuity card procedure. At corrected ages of 6 and 9 months, eyes were examined for structural outcome. Outcomes for the 2 treatment groups of eyes were compared using chi2 analysis, combining data for bilateral and asymmetric cases. Grating acuity results showed a reduction in unfavorable visual acuity outcomes with earlier treatment, from 19.5% to 14.5% (P =.01). Unfavorable structural outcomes were reduced from 15.6% to 9.1% (P<.001) at 9 months. Further analysis supported retinal ablative therapy for eyes with type 1 ROP, defined as zone I, any stage ROP with plus disease (a degree of dilation and tortuosity of the posterior retinal blood vessels meeting or exceeding that of a standard photograph); zone I, stage 3 ROP without plus disease; or zone II, stage 2 or 3 ROP with plus disease. The analysis supported a wait-and-watch approach to type 2 ROP, defined as zone I, stage 1 or 2 ROP without plus disease or zone II, stage 3 ROP without plus disease. These eyes should be considered for treatment only if they progress to type 1 or threshold ROP. Early treatment of high-risk prethreshold ROP significantly reduced unfavorable outcomes to a clinically important degree. Additional analyses led to modified recommendations for the use of peripheral retinal ablation in eyes with ROP. Long-term follow-up is being conducted to learn whether the benefits noted in the first year after birth will persist into childhood.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

            Retinopathy of prematurity is a leading cause of childhood blindness worldwide. Peripheral retinal ablation with conventional (confluent) laser therapy is destructive, causes complications, and does not prevent all vision loss, especially in cases of retinopathy of prematurity affecting zone I of the eye. Case series in which patients were treated with vascular endothelial growth factor inhibitors suggest that these agents may be useful in treating retinopathy of prematurity. We conducted a prospective, controlled, randomized, stratified, multicenter trial to assess intravitreal bevacizumab monotherapy for zone I or zone II posterior stage 3+ (i.e., stage 3 with plus disease) retinopathy of prematurity. Infants were randomly assigned to receive intravitreal bevacizumab (0.625 mg in 0.025 ml of solution) or conventional laser therapy, bilaterally. The primary ocular outcome was recurrence of retinopathy of prematurity in one or both eyes requiring retreatment before 54 weeks' postmenstrual age. We enrolled 150 infants (total sample of 300 eyes); 143 infants survived to 54 weeks' postmenstrual age, and the 7 infants who died were not included in the primary-outcome analyses. Retinopathy of prematurity recurred in 4 infants in the bevacizumab group (6 of 140 eyes [4%]) and 19 infants in the laser-therapy group (32 of 146 eyes [22%], P=0.002). A significant treatment effect was found for zone I retinopathy of prematurity (P=0.003) but not for zone II disease (P=0.27). Intravitreal bevacizumab monotherapy, as compared with conventional laser therapy, in infants with stage 3+ retinopathy of prematurity showed a significant benefit for zone I but not zone II disease. Development of peripheral retinal vessels continued after treatment with intravitreal bevacizumab, but conventional laser therapy led to permanent destruction of the peripheral retina. This trial was too small to assess safety. (Funded by Research to Prevent Blindness and others; ClinicalTrials.gov number, NCT00622726.).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              Deep Learning Is Effective for Classifying Normal versus Age-Related Macular Degeneration OCT Images

              The advent of Electronic Medical Records (EMR) with large electronic imaging databases along with advances in deep neural networks with machine learning has provided a unique opportunity to achieve milestones in automated image analysis. Optical coherence tomography (OCT) is the most commonly obtained imaging modality in ophthalmology and represents a dense and rich dataset when combined with labels derived from the EMR. We sought to determine if deep learning could be utilized to distinguish normal OCT images from images from patients with Age-related Macular Degeneration (AMD).
                Bookmark

                Author and article information

                Journal
                JAMA Ophthalmology
                JAMA Ophthalmol
                American Medical Association (AMA)
                2168-6165
                July 01 2018
                July 01 2018
                : 136
                : 7
                : 803
                Affiliations
                [1 ]Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown
                [2 ]Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland
                [3 ]Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago
                [4 ]Department of Electrical and Computer Engineering, Northeastern University, Boston, Massachusetts
                [5 ]Massachusetts General Hospital and Brigham and Women’s Hospital Center for Clinical Data Science, Boston
                [6 ]Department of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Portland
                Article
                10.1001/jamaophthalmol.2018.1934
                6136045
                29801159
                45872934-f14e-4c21-9612-9e3ba9da63ca
                © 2018
                History

                Comments

                Comment on this article